Stockley's Drug Interactions - A Source Book of Interactions, Their Mechanisms, Clinical Importance and Management - Grand Format

Stockley's Drug Interactions, edited by Claire L Preston, remains the world's most comprehensive and authoritative international reference book on drug interactions. Based upon thousands of published papers and reports It : Covers interactions between therapeutic drugs, proprietary medicines, herbal medicines, foods, drinks, and drugs of abuse ; Contains in-depth yet concise monographs in an easy-to-read format ; Provides comprehensive details of the clinical evidence for the interactions under discussion, an assessment of their clinical importance, and clear guidance on managing the interaction in practice ; Each monograph has a brief summary of the interaction- perfect for the busy healthcare professional ; Based on published sources and fully referenced throughout ; Contains almost 5000 monographs ; Global coverage—inclusion of drugs used worldwide.
For the 12th edition : Almost 500 new monographs added ; Many existing monographs have been reviewed, revalidated, and updated ; New classification tables of inhibitors and substrates of the drug transporter proteins BCRP, MATE, OAT, OATP, and OCT, based on clinical pharmacokinetic data ; Revised classification tables of inhibitors, inducers, and substrates of CYP450 enzymes, based on clinical pharmacokinetic data ; A new chapter on the Monoclonal Antibodies, bringing all the monographs on these drugs together into one place in the publication ; A comprehensive update and restructure of the monographs on the antiepileptic drugs, the atypical antipsychotics, HCV-protease inhibitors, HIV protease inhibitors, NRTIs, and NNRTIs, in-line with published literature ; An updated list of drugs that have a risk of prolonging the QT interval ; A new list of drugs that can lower the seizure threshold ; The addition of new drugs, including cangrelor, the cyclin-dependent kinase inhibitors, abemaciclib, palbociclib, and ribociclib, ertugliflozin, idelalisib, isavuconazole, lumacaftor, lurasidone, naloxegol, the neurokinin-1 receptor antagonists, netupitant and rolapitant, safinamide, semaglutide,tedizolid, venetoclax, and vorapaxar.